| PE02.04 | Variation in neutralization susceptibility of HIV-1 Indian subtype C to potent and broadly neutralizing monoclonal antibodies (bnAbs) having distinct epitope specificities | E-poster | Broadly neutralizing antibodies |
| PE02.05 | Antibody genetic diversity with large structural variation in a South African population | E-poster | Broadly neutralizing antibodies |
| PE02.06 | Founder Env-specific IgM B cell responses during acute HIV-1 infection associate with the development of broadly neutralizing antibodies | E-poster | Broadly neutralizing antibodies |
| PE02.07 | IgG3 HIV broadly neutralizing antibodies show improved neutralization potency and phagocytosis compared to IgG1 variants | E-poster | Broadly neutralizing antibodies |
| PE02.08 | Defining the mechanism for varied neutralization potency of HIV neutralizing antibodies with identical variable regions but differing isotype | E-poster | Broadly neutralizing antibodies |
| PE02.09 | 35O22 and VRC44 define a new highly glycan-dependent multidonor class of HIV-1 gp120:gp41 interface-directed bnAbs | E-poster | Broadly neutralizing antibodies |
| PE02.10 | Precursor frequencies of naïve B cells targeting HIV candidate immunogens | E-poster | Broadly neutralizing antibodies |
| PE02.11 | Low dose administration of unmodified 10E8v4, but not FcγR/complement dual enhanced or dual ablated 10E8v4 variants, decreases viremia in SHIV challenged macaques | E-poster | Broadly neutralizing antibodies |
| PE02.12 | Functional convergence of clonally related but genetically distinct bNAbs that target the V3-glycan epitope | E-poster | Broadly neutralizing antibodies |
| PE02.13 | Enhanced protection at the site of challenge of rhesus macaques that receive PGT121 one week prior to intravaginal challenge with SHIV-SF162P3 | E-poster | Broadly neutralizing antibodies |